Sign In
Buy EDIT
$2.78
-0.0400 (-1.42%)
At Close: Jun 03, 2026
Gene Therapy Companies Are Racing to Cure Sickle Cell. That Would Open the Door to Curing Dozens of Other Diseases.
03:52pm, Saturday, 25'th Jul 2020
Successful treatments would demonstrate the potential for gene therapy—and boost a number of biotech companies.
Could Editas Medicine Be a Millionaire-Maker Stock?
11:03am, Saturday, 25'th Jul 2020
CRISPR gene editing became a big story around 2012, and in the few years that followed, the promise of the technology spurred the founding of several biotechs focused on using it to treat diseases. E
Is CRISPR Therapeutics Stock a Buy? | The Motley Fool
10:45am, Saturday, 25'th Jul 2020
The gene-editing pioneer is a favorite among biotech investors and its stock is hitting new highs.
Gene Therapy Companies Are Racing to Cure Sickle Cell. That Would Open the Door to Curing Dozens of Other Diseases.
08:23pm, Friday, 24'th Jul 2020
Successful treatments would demonstrate the potential for gene therapy—and boost a number of biotech companies.
Editas Medicine to Host Conference Call Discussing Second Quarter 2020 Results and Corporate Update
08:01pm, Thursday, 23'rd Jul 2020
CAMBRIDGE, Mass., July 23, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Thursday,
2 Best Gene-Editing Stocks to Buy in July
11:07am, Tuesday, 21'st Jul 2020
Gene-editing stocks are favorites for biotech industry speculators thanks to their air of high-tech mystique and their potential to make blockbuster therapies. According to Market Research Future, th
Editas Medicine Inc (NASDAQ:EDIT) Shares Bought by Wells Fargo & Company MN
08:26pm, Thursday, 16'th Jul 2020
Wells Fargo & Company MN boosted its stake in shares of Editas Medicine Inc (NASDAQ:EDIT) by 2.8% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 57
Advisor Group Holdings Inc. Makes New $418,000 Investment in Editas Medicine Inc (NASDAQ:EDIT)
04:52pm, Thursday, 16'th Jul 2020
Advisor Group Holdings Inc. bought a new position in shares of Editas Medicine Inc (NASDAQ:EDIT) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Ex
Brokerages Expect Editas Medicine Inc (NASDAQ:EDIT) Will Post Quarterly Sales of $6.14 Million
07:52pm, Wednesday, 15'th Jul 2020
Brokerages forecast that Editas Medicine Inc (NASDAQ:EDIT) will announce $6.14 million in sales for the current quarter, according to Zacks. Four analysts have issued estimates for Editas Medicine’s
What You Need To Know About Editas Medicine, Inc.'s (NASDAQ:EDIT) Investor Composition
12:45pm, Sunday, 12'th Jul 2020
A look at the shareholders of Editas Medicine, Inc. (NASDAQ:EDIT) can tell us which group is most powerful. Generally...
3 Top Biotech Stocks to Watch in July
11:31am, Thursday, 09'th Jul 2020
These three stocks are positioned for growth -- but investors must tread carefully in the short term.
Editas Medicine and Azzur Group Announce a Multi-year Agreement for EDIT-301 and EDIT-201 Manufacturing
01:00pm, Tuesday, 07'th Jul 2020
CAMBRIDGE, Mass., and WALTHAM, Mass., July 07, 2020 -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, and Azzur Cleanrooms on Demand™ (COD), an Azzur.
Parametric Portfolio Associates LLC Acquires 6,865 Shares of Editas Medicine Inc (NASDAQ:EDIT)
04:28am, Sunday, 05'th Jul 2020
Parametric Portfolio Associates LLC raised its holdings in shares of Editas Medicine Inc (NASDAQ:EDIT) by 19.5% during the first quarter, according to its most recent disclosure with the Securities an
Morgan Stanley Sells 365,722 Shares of Editas Medicine Inc (NASDAQ:EDIT)
06:16am, Friday, 03'rd Jul 2020
Morgan Stanley lowered its stake in Editas Medicine Inc (NASDAQ:EDIT) by 32.4% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The
Better Buy: Editas Medicine vs. Intellia
03:32pm, Thursday, 02'nd Jul 2020
Which of these companies that are developing cutting-edge gene-editing technologies is the better buy for investors?
